Eli Lilly to acquire Morphic in $3.2B deal

Pharmaceutical giant Eli Lilly (LLY) has reached an agreement to purchase biopharmaceutical company Morphic (MORF) in a deal valued at $3.2 billion. This strategic move marks a notable expansion in Eli Lilly's portfolio and research capabilities.

Yahoo Finance health reporter Anjalee Khemlani explores the benefits of this deal for both companies and the broader pharmaceutical industry.

About Yahoo Finance:

Yahoo Finance provides free stock ticker data, up-to-date news, portfolio management resources, comprehensive market data, advanced tools, and more information to help you manage your financial life.

- Get the latest news and data at finance.yahoo.com

- Download the Yahoo Finance app on Apple (https://apple.co/3Rten0R) or Android (https://bit.ly/3t8UnXO)

- Follow Yahoo Finance on social:

X:   / yahoofinance  
Instagram: https://www.instagram.com/yahoofinanc...
TikTok: https://www.tiktok.com/@yahoofinance?...
Facebook:   / yahoofinance  
LinkedIn:   / yahoo-finance  

#elililly #yahoofinance #pharma